In:
International Journal of Cancer, Wiley, Vol. 145, No. 8 ( 2019-10-15), p. 2114-2121
Abstract:
What's new? A standard treatment for breast cancer is aromatase inhibitors (AIs), but common adverse events including musculoskeletal pain can cause early discontinuation. This study analyzed the influence of preexisting muscle/limb pain and joint pain on the development of AI‐induced musculoskeletal adverse events. Women without preexisting muscle/limb or joint pain have the greatest increase in pain after starting adjuvant AI therapy. Women with preexisting pain have higher pain scores, but a smaller increase in pain in comparison. The main increase in pain scores takes place in the first 6 months of endocrine treatment, calling for greater physician attention during this time window.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8